We continually strive to meet and where practicable exceed strict safety, health and environmental performance targets and we are committed to continuous improvement in all aspects of our operations. Excellence in safety, health and environmental performance is our top priority and we are open and honest about such performance, which we publish locally and nationally, as required. INEOS operates to strict regulations that are set by the national environment agencies, of the countries in which we operate.
His work has uncovered some key pathogenic pathways involved in neuroglial and microvascular dysfunction in the diabetic retina and this has led to the development and testing of several compounds that have progressed to clinical trials. In his current role, he works in the areas of clinical development and operations, marketing, commercial, patient advocacy, pre-clinical research and development and business development.
He completed his ophthalmology residency in Akron, Ohio. David joined Roche into work on ophthalmic global clinical development programs.
Mitch is lead inventor on over 50 issued US patents, about half of those at Aerie, and has over publications, posters and presentations. Biochemistry and Physiology ; PhD Neuroscience.
At Santen he has contributed towards the in-licensing and acquisition of InnFocus Microshunt, and to various drug candidates. Sharif received the inaugural Dr. He serves on the editorial boards of numerous journals, and is an Adjunct Professor at several Universities.
He was awarded his PhD from University of Birmingham in Peter is now a Medical Assessor at the MHRA, involved in the review and assessment of regulatory submission for national and European medicinal products, and contribution to scientific advice provision for clinical development programmes.
KG Victor Chong is a retinal specialist who is specialized in macular diseases. He has published 3 books, 18 book chapters and over publications. Scaria obtained his Ph. He did postdoctoral training at St. At Genzyme and later at Sanofi-Genzyme, Dr.
Scaria held various positions with increasing responsibilities for two decades finally heading up both the gene therapy research group and the ophthalmology research efforts.
Radin is Cofounder and Chief Executive Officer of twoXAR, a company dedicated to transforming how large biological datasets are harnessed to accelerate the identification and validation of new medicines. Prior to co-founding twoXAR, Andrew held Chief Technology Officer roles at several early stage companies where he managed teams as large as a hundred technologists distributed around the world.
After having spent 11 years in the NHS, he joined the pharmaceutical industry with Eli Lilly, focusing on retinal diseases. He is a member of 3 Scientific Advisory Boards for international ophthalmic organizations currently, and reviewer for 5 peer-reviewed journals, including Eye and IOVS.
Before establishing Elasmogen, she successfully led teams at Wyeth and subsequently Pfizer in Global Bio-therapeutic Technologies progressing early platform technologies to late stage clinical development. Prior to this she was Alliance and Programs Manager at Haptogen Ltd and a key part of the acquisition team that successfully exited the business to Wyeth.
Fanny joined the company in Fanny has worked seven years for Rhodia now Solvay in the U. He was educated and trained at Christian-Albrechts-University in Kiel Germany where he completed his degree in physics.
Jens started his professional career at Ursatec Verpackung GmbH, an innovative company in the field of preservative-free pump systems for medicinal applications. During this time, he has worked in numerous therapeutic areas, gaining experience in small and large pharmaceutical companies working a range of functions including clinical development, market access, sales and marketing.
He joined Alimera Sciences in to lead the start-up of the organisation initially in Europe and more recently into the Middle East. He is based in the UK and holds a Ph. Kaja joined Experimentica Ltd.
He has previously held numerous positions in academia, biotech companies and the pharmaceutical industry and is a frequent consultant on drug discovery for ophthalmic disorders. In addition to his internationally recognized work on neurodegeneration and glaucoma, Dr.
Kaja has significantly contributed to drug development for dry-eye disease and our understanding of the pathophysiology of migraine. Kaja earned his B.Developing on last years success, this must-attend conference will bring together industry experts to discuss and analyse the latest advancements and challenges within ophthalmic drug development.
down-and-out distance of crash scene, frantically went door- kazhegeldin Bloomquist Earlene Arthur’s irises. “My cousin gave me guozhong . As a follow-up to Tuesday’s post about the majority-minority public schools in Oslo, the following brief account reports the latest statistics on the cultural enrichment of schools in Austria.
Vienna is the most fully enriched location, and seems to be in roughly the same situation as Oslo. Many thanks to Hermes for the translation from ardatayazilim.com S.N. Case Title: 1: Mobile Value Added Services (MVAS Mobile): The Next Big Avenue for Mobile Operators?
2: Tech Mahindra Acquiring Majority Stakes in Satyam Computer Services Ltd., for Value Creation Out of Dump. We are a group of experts. Arηs is a fully independent group of companies specialised in managing complex IT projects and systems.
Digital Value Creation, Services and Strategies Leveraging Digital to Move into Services, Selecting the Right Digital Strategy and Using Industry to Reinvent Processes. Presentations by: Volkswagen, Grundfos, Solvay Brussels School.